Roles of Traditional and Next-Generation Probiotics on Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A Systematic Review and Network Meta-Analysis
Non-alcoholic fatty liver disease (NAFLD) and its progressive stage, non-alcoholic steatohepatitis (NASH), are becoming one of the most common chronic liver diseases globally. Lifestyle interventions such as weight reduction, increased physical activity, and maintaining healthy diets play a pivotal...
Saved in:
Published in | Antioxidants Vol. 13; no. 3; p. 329 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
MDPI AG
07.03.2024
MDPI |
Subjects | |
Online Access | Get full text |
ISSN | 2076-3921 2076-3921 |
DOI | 10.3390/antiox13030329 |
Cover
Abstract | Non-alcoholic fatty liver disease (NAFLD) and its progressive stage, non-alcoholic steatohepatitis (NASH), are becoming one of the most common chronic liver diseases globally. Lifestyle interventions such as weight reduction, increased physical activity, and maintaining healthy diets play a pivotal role in managing NAFLD/NASH. Recent studies suggest that the gut microbiome is associated with the pathogenesis of NAFLD/NASH, prompting microbiome-targeted therapy to emerge as a new therapeutic option for NAFLD/NASH. We conducted a systematic review based on the PRISMA statement and employed network meta-analysis to investigate the effects of traditional probiotics and next-generation probiotics (NGPs) on NAFLD/NASH. Comparative analysis reveals that traditional probiotics primarily reduce liver fat deposition and inflammation by improving gut microbiota composition, enhancing intestinal barrier function, and modulating immune responses. In contrast, NGPs demonstrate a more significant therapeutic potential, attributed to their direct effects on inhibiting oxidative stress and their ability to enhance the production of short-chain fatty acids (SCFAs), NGPs appear as a new potential strategy for the management of NAFLD/NASH through their dual action of directly inhibiting oxidative stress and enhancing SCFA production, highlighting the importance of understanding and utilizing the direct and indirect regulatory mechanisms of oxidative stress in the management of NAFLD/NASH. |
---|---|
AbstractList | Non-alcoholic fatty liver disease (NAFLD) and its progressive stage, non-alcoholic steatohepatitis (NASH), are becoming one of the most common chronic liver diseases globally. Lifestyle interventions such as weight reduction, increased physical activity, and maintaining healthy diets play a pivotal role in managing NAFLD/NASH. Recent studies suggest that the gut microbiome is associated with the pathogenesis of NAFLD/NASH, prompting microbiome-targeted therapy to emerge as a new therapeutic option for NAFLD/NASH. We conducted a systematic review based on the PRISMA statement and employed network meta-analysis to investigate the effects of traditional probiotics and next-generation probiotics (NGPs) on NAFLD/NASH. Comparative analysis reveals that traditional probiotics primarily reduce liver fat deposition and inflammation by improving gut microbiota composition, enhancing intestinal barrier function, and modulating immune responses. In contrast, NGPs demonstrate a more significant therapeutic potential, attributed to their direct effects on inhibiting oxidative stress and their ability to enhance the production of short-chain fatty acids (SCFAs), NGPs appear as a new potential strategy for the management of NAFLD/NASH through their dual action of directly inhibiting oxidative stress and enhancing SCFA production, highlighting the importance of understanding and utilizing the direct and indirect regulatory mechanisms of oxidative stress in the management of NAFLD/NASH. Non-alcoholic fatty liver disease (NAFLD) and its progressive stage, non-alcoholic steatohepatitis (NASH), are becoming one of the most common chronic liver diseases globally. Lifestyle interventions such as weight reduction, increased physical activity, and maintaining healthy diets play a pivotal role in managing NAFLD/NASH. Recent studies suggest that the gut microbiome is associated with the pathogenesis of NAFLD/NASH, prompting microbiome-targeted therapy to emerge as a new therapeutic option for NAFLD/NASH. We conducted a systematic review based on the PRISMA statement and employed network meta-analysis to investigate the effects of traditional probiotics and next-generation probiotics (NGPs) on NAFLD/NASH. Comparative analysis reveals that traditional probiotics primarily reduce liver fat deposition and inflammation by improving gut microbiota composition, enhancing intestinal barrier function, and modulating immune responses. In contrast, NGPs demonstrate a more significant therapeutic potential, attributed to their direct effects on inhibiting oxidative stress and their ability to enhance the production of short-chain fatty acids (SCFAs), NGPs appear as a new potential strategy for the management of NAFLD/NASH through their dual action of directly inhibiting oxidative stress and enhancing SCFA production, highlighting the importance of understanding and utilizing the direct and indirect regulatory mechanisms of oxidative stress in the management of NAFLD/NASH.Non-alcoholic fatty liver disease (NAFLD) and its progressive stage, non-alcoholic steatohepatitis (NASH), are becoming one of the most common chronic liver diseases globally. Lifestyle interventions such as weight reduction, increased physical activity, and maintaining healthy diets play a pivotal role in managing NAFLD/NASH. Recent studies suggest that the gut microbiome is associated with the pathogenesis of NAFLD/NASH, prompting microbiome-targeted therapy to emerge as a new therapeutic option for NAFLD/NASH. We conducted a systematic review based on the PRISMA statement and employed network meta-analysis to investigate the effects of traditional probiotics and next-generation probiotics (NGPs) on NAFLD/NASH. Comparative analysis reveals that traditional probiotics primarily reduce liver fat deposition and inflammation by improving gut microbiota composition, enhancing intestinal barrier function, and modulating immune responses. In contrast, NGPs demonstrate a more significant therapeutic potential, attributed to their direct effects on inhibiting oxidative stress and their ability to enhance the production of short-chain fatty acids (SCFAs), NGPs appear as a new potential strategy for the management of NAFLD/NASH through their dual action of directly inhibiting oxidative stress and enhancing SCFA production, highlighting the importance of understanding and utilizing the direct and indirect regulatory mechanisms of oxidative stress in the management of NAFLD/NASH. |
Author | Tan, Jen Kit Zhu, Yuezhi Liu, Jia Goon, Jo Aan |
AuthorAffiliation | 2 Department of Nursing, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia 1 Department of Biochemistry, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia |
AuthorAffiliation_xml | – name: 2 Department of Nursing, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia – name: 1 Department of Biochemistry, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur 56000, Malaysia |
Author_xml | – sequence: 1 givenname: Yuezhi surname: Zhu fullname: Zhu, Yuezhi – sequence: 2 givenname: Jen Kit orcidid: 0000-0002-0824-0581 surname: Tan fullname: Tan, Jen Kit – sequence: 3 givenname: Jia surname: Liu fullname: Liu, Jia – sequence: 4 givenname: Jo Aan orcidid: 0000-0003-1757-3780 surname: Goon fullname: Goon, Jo Aan |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38539862$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkk1PGzEQhlcVVaGUa4-VpV7gsNQfu7HdC4qgAaQ0rQg9W17vLHG6Wae2E8g_68-rQ0JFkCrVPtgav_P4ndG8zfY610GWvSf4lDGJP-kuWvdAGE6bylfZAcW8lzNJyd6z-352FMIUpyUJE1i-yfaZKJkUPXqQ_b5xLQTkGnTrdW0Tr9Mt0l2NRvAQ80vowOt1FH33rrIuWpPUHRq5Lu-3xk1caw0a6BhXaGiX4NGFDaADoONRfzC8ONmwdtTjCDq6CcwTONqwVo6vTj6jPhqvQoRZCht0A0sL91sn8d75n-grRJ33k79VsOFd9rrRbYCj7XmY_Rh8uT2_yoffLq_P-8PclETEnDai5BxDVRdNRQmBgpVUlripTEEaUfU4T62ESjNSAit7Da4oJqbSgGUpWc0Os-sNt3Z6qubezrRfKaetegw4f6e0T4ZbULzBWBihOSdN0WONriQvWCEZkZoIIRPrbMOaL6oZ1Aa66HW7A9196exE3bmlIlj2BOEiEY63BO9-LSBENbPBQNvqDtwiKIYLnL6kXP6HlBQYF0LQJP34Qjp1C58aHRSVghMpabkGfnju_q_tp2FKgmIjMN6F4KFRxsbH4UnF2DZVodZjq3bHNqWdvkh7Iv8j4Q_r6--I |
CitedBy_id | crossref_primary_10_12944_CRNFSJ_12_2_2 crossref_primary_10_1016_j_nutos_2024_08_009 crossref_primary_10_1186_s10020_024_00945_1 crossref_primary_10_1016_j_fbio_2024_105454 crossref_primary_10_3389_fmed_2024_1490929 crossref_primary_10_3390_biomedicines12112529 crossref_primary_10_1016_j_clnesp_2024_07_1024 crossref_primary_10_1016_j_ecoenv_2025_117969 |
Cites_doi | 10.1186/s12876-019-1047-4 10.1007/s10620-011-1887-4 10.1111/jgh.13742 10.4103/2008-7802.178533 10.3390/ijms24032844 10.1111/1750-3841.15367 10.1039/D0FO01954B 10.1080/13543784.2020.1716333 10.3389/fnut.2022.1037696 10.1016/j.redox.2018.01.009 10.1016/j.tjnut.2023.05.019 10.14715/cmb/2021.67.5.9 10.3390/nu12113225 10.15403/jgld.2014.1121.271.kby 10.1016/S1665-2681(19)31364-X 10.3168/jds.2014-8500 10.3390/ijms23042325 10.1038/s41586-023-06378-w 10.1093/ajcn/nqy358 10.1128/AEM.03004-19 10.3350/cmh.2018.0006 10.3389/fimmu.2022.1047570 10.3390/nu13093211 10.3389/fimmu.2021.678360 10.1016/j.addr.2021.113869 10.1016/bs.pmbts.2022.07.004 10.1111/1751-2980.12561 10.1038/s41598-022-06414-1 10.1016/j.aohep.2022.100769 10.3390/diseases7010027 10.1371/journal.pone.0263931 10.1016/j.clnesp.2020.06.020 10.3390/nu13093192 10.3390/ph16050712 10.1016/j.biopha.2021.111235 10.1080/07315724.2015.1031355 10.3389/fmicb.2023.1123547 10.3390/microorganisms10020297 10.3389/fcimb.2022.997018 10.1016/j.eng.2020.01.017 10.1097/MD.0000000000021464 10.3390/nu12092762 10.1128/Spectrum.00484-21 10.3390/biomedicines9060687 10.1080/17461391.2019.1571114 10.3389/fendo.2022.1087260 10.3390/antiox10122001 10.1053/j.gastro.2020.01.031 10.2147/DMSO.S146339 10.1007/s00018-021-04080-6 10.3390/microorganisms10020452 10.3945/ajcn.113.068890 10.3389/fcimb.2022.863949 10.3390/nu14142945 10.1053/j.gastro.2020.01.051 10.1038/s41598-019-42059-3 10.1080/19490976.2023.2221485 10.3390/biomedicines11020640 10.1530/JOE-20-0018 10.1007/s00394-018-1721-2 10.1016/j.biopha.2023.114300 10.1186/s12876-021-01660-5 10.1016/j.foodres.2019.108590 10.2147/PHMT.S188989 10.1136/bmjgast-2019-000315 10.1093/jn/nxab392 10.1017/S0007114517000204 10.1155/2022/5633403 |
ContentType | Journal Article |
Copyright | 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2024 by the authors. 2024 |
Copyright_xml | – notice: 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2024 by the authors. 2024 |
DBID | AAYXX CITATION NPM 7QR 7T5 7TO 8FD 8FE 8FH ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FR3 GNUQQ H94 HCIFZ LK8 M7P P64 PHGZM PHGZT PIMPY PKEHL PQEST PQGLB PQQKQ PQUKI PRINS 7X8 7S9 L.6 5PM DOA |
DOI | 10.3390/antiox13030329 |
DatabaseName | CrossRef PubMed Chemoreception Abstracts Immunology Abstracts Oncogenes and Growth Factors Abstracts Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Journals ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Engineering Research Database ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection Biological Sciences Biological Science Database Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic (New) ProQuest Publicly Available Content ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic AGRICOLA AGRICOLA - Academic PubMed Central (Full Participant titles) DOAJ Open Access Full Text |
DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest Central Student Oncogenes and Growth Factors Abstracts Technology Research Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences Natural Science Collection ProQuest Central Korea Biological Science Collection AIDS and Cancer Research Abstracts Chemoreception Abstracts ProQuest Central (New) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Biological Science Database ProQuest SciTech Collection Biotechnology and BioEngineering Abstracts ProQuest One Academic UKI Edition Immunology Abstracts Engineering Research Database ProQuest One Academic ProQuest One Academic (New) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
DatabaseTitleList | AGRICOLA CrossRef MEDLINE - Academic PubMed Publicly Available Content Database |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Engineering |
EISSN | 2076-3921 |
ExternalDocumentID | oai_doaj_org_article_7f008c8a771f463fab974349319a1889 PMC10968178 38539862 10_3390_antiox13030329 |
Genre | Journal Article Review |
GrantInformation_xml | – fundername: HEZE HUIREN CHINESE MEDICINE HOSPITAL grantid: FF-2022-261 – fundername: UNIVERSITI KEBANGSAAN MALAYSIA grantid: DPK-2022-007 |
GroupedDBID | 53G 5VS 8FE 8FH AADQD AAFWJ AAHBH AAYXX ADBBV AFKRA AFPKN AFZYC ALMA_UNASSIGNED_HOLDINGS AOIJS BBNVY BCNDV BENPR BHPHI CCPQU CITATION GROUPED_DOAJ HCIFZ HYE IAO IHR ITC KQ8 LK8 M48 M7P MODMG M~E OK1 PGMZT PHGZM PHGZT PIMPY PQGLB PROAC PUEGO RPM NPM 7QR 7T5 7TO 8FD ABUWG AZQEC DWQXO FR3 GNUQQ H94 P64 PKEHL PQEST PQQKQ PQUKI PRINS 7X8 7S9 L.6 5PM |
ID | FETCH-LOGICAL-c518t-2f85770ebd4fb211e4352950fbc41f8b677339eba315e356f0b201cbae09593d3 |
IEDL.DBID | M48 |
ISSN | 2076-3921 |
IngestDate | Wed Aug 27 01:31:46 EDT 2025 Tue Sep 30 17:09:33 EDT 2025 Fri Sep 05 09:57:43 EDT 2025 Thu Sep 04 20:06:15 EDT 2025 Fri Jul 25 11:51:33 EDT 2025 Thu Jan 02 22:37:57 EST 2025 Thu Apr 24 23:09:05 EDT 2025 Wed Oct 01 03:03:25 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | antioxidant NAFLD/NASH traditional probiotics short-chain fatty acids (SCFAs) next-generation probiotics (NGPs) |
Language | English |
License | https://creativecommons.org/licenses/by/4.0 Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c518t-2f85770ebd4fb211e4352950fbc41f8b677339eba315e356f0b201cbae09593d3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
ORCID | 0000-0002-0824-0581 0000-0003-1757-3780 |
OpenAccessLink | https://doaj.org/article/7f008c8a771f463fab974349319a1889 |
PMID | 38539862 |
PQID | 2987199259 |
PQPubID | 2032435 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_7f008c8a771f463fab974349319a1889 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10968178 proquest_miscellaneous_3040434279 proquest_miscellaneous_3014004882 proquest_journals_2987199259 pubmed_primary_38539862 crossref_citationtrail_10_3390_antiox13030329 crossref_primary_10_3390_antiox13030329 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 20240307 |
PublicationDateYYYYMMDD | 2024-03-07 |
PublicationDate_xml | – month: 3 year: 2024 text: 20240307 day: 7 |
PublicationDecade | 2020 |
PublicationPlace | Switzerland |
PublicationPlace_xml | – name: Switzerland – name: Basel |
PublicationTitle | Antioxidants |
PublicationTitleAlternate | Antioxidants (Basel) |
PublicationYear | 2024 |
Publisher | MDPI AG MDPI |
Publisher_xml | – name: MDPI AG – name: MDPI |
References | Yao (ref_15) 2021; 7 Michel (ref_69) 2020; 29 ref_12 Esposito (ref_13) 2022; 79 Malaguarnera (ref_42) 2012; 57 ref_56 ref_11 Khan (ref_16) 2023; 620 Mofidi (ref_29) 2017; 117 ref_55 ref_10 ref_53 ref_52 Sun (ref_14) 2019; 126 ref_19 ref_18 ref_17 Eslamparast (ref_26) 2014; 99 Shavakhi (ref_24) 2013; 4 Amiri (ref_67) 2022; 9 Scorletti (ref_33) 2020; 158 Abhari (ref_31) 2020; 39 Escouto (ref_45) 2023; 153 Farzanegi (ref_20) 2019; 19 Kim (ref_59) 2020; 86 ref_61 ref_60 Raftar (ref_54) 2022; 12 Zhu (ref_49) 2022; 68 Li (ref_57) 2022; 13 ref_21 ref_65 ref_64 ref_63 Borrelli (ref_22) 2018; 15 Purohit (ref_7) 2022; 191 Cirillo (ref_3) 2019; 10 Sepideh (ref_27) 2016; 35 Crommen (ref_47) 2022; 152 Yang (ref_51) 2020; 11 ref_70 Ahn (ref_37) 2019; 9 Sarwar (ref_4) 2018; 11 ref_34 Rong (ref_62) 2022; 13 Han (ref_58) 2023; 15 ref_38 Kobyliak (ref_36) 2018; 27 Deng (ref_68) 2020; 245 Beisner (ref_66) 2021; 12 Asgharian (ref_28) 2016; 7 Wong (ref_39) 2013; 12 Nabavi (ref_25) 2014; 97 Bomhof (ref_32) 2019; 58 Padda (ref_2) 2021; 13 Manzhalii (ref_35) 2017; 18 Aller (ref_43) 2011; 15 ref_1 Chen (ref_40) 2019; 109 Kumar (ref_23) 2021; 176 Behrouz (ref_30) 2020; 85 Duseja (ref_44) 2019; 6 Barcelos (ref_46) 2023; 28 ref_9 ref_8 Zhou (ref_50) 2017; 32 ref_5 Sayari (ref_48) 2018; 24 ref_6 Cai (ref_41) 2020; 99 (ref_71) 2020; 158 |
References_xml | – volume: 13 start-page: e17321 year: 2021 ident: ref_2 article-title: Non-Alcoholic Fatty Liver Disease and Its Association With Diabetes Mellitus publication-title: Cureus – ident: ref_9 doi: 10.1186/s12876-019-1047-4 – volume: 57 start-page: 545 year: 2012 ident: ref_42 article-title: Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis publication-title: Dig. Dis. Sci. doi: 10.1007/s10620-011-1887-4 – volume: 32 start-page: 1640 year: 2017 ident: ref_50 article-title: Clostridium butyricum B1 alleviates high-fat diet-induced steatohepatitis in mice via enterohepatic immunoregulation publication-title: J. Gastroenterol. Hepatol. doi: 10.1111/jgh.13742 – volume: 7 start-page: 59 year: 2016 ident: ref_28 article-title: The Effect of Symbiotic Supplementation on Liver Enzymes, C-reactive Protein and Ultrasound Findings in Patients with Non-alcoholic Fatty Liver Disease: A Clinical Trial publication-title: Int. J. Prev. Med. doi: 10.4103/2008-7802.178533 – ident: ref_1 doi: 10.3390/ijms24032844 – volume: 85 start-page: 3611 year: 2020 ident: ref_30 article-title: Effects of probiotic and prebiotic supplementation on metabolic parameters, liver aminotransferases, and systemic inflammation in nonalcoholic fatty liver disease: A randomized clinical trial publication-title: J. Food Sci. doi: 10.1111/1750-3841.15367 – volume: 11 start-page: 10675 year: 2020 ident: ref_51 article-title: Amelioration of non-alcoholic fatty liver disease by sodium butyrate is linked to the modulation of intestinal tight junctions in db/db mice publication-title: Food Funct. doi: 10.1039/D0FO01954B – volume: 29 start-page: 93 year: 2020 ident: ref_69 article-title: Effectiveness of lifestyle interventions in NAFLD (nonalcoholic fatty liver disease)—How are clinical trials affected publication-title: Expert Opin. Investig. Drugs. doi: 10.1080/13543784.2020.1716333 – volume: 9 start-page: 1037696 year: 2022 ident: ref_67 article-title: Mechanistic insights into the pleiotropic effects of butyrate as a potential therapeutic agent on NAFLD management: A systematic review publication-title: Front. Nutr. doi: 10.3389/fnut.2022.1037696 – volume: 15 start-page: 467 year: 2018 ident: ref_22 article-title: Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches publication-title: Redox Biol. doi: 10.1016/j.redox.2018.01.009 – volume: 15 start-page: 1090 year: 2011 ident: ref_43 article-title: Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: A double blind randomized clinical trial publication-title: Eur. Rev. Med. Pharmacol. Sci. – volume: 153 start-page: 1984 year: 2023 ident: ref_45 article-title: Probiotic Supplementation, Hepatic Fibrosis, and the Microbiota Profile in Patients with Nonalcoholic Steatohepatitis: A Randomized Controlled Trial publication-title: J. Nutr. doi: 10.1016/j.tjnut.2023.05.019 – volume: 68 start-page: 64 year: 2022 ident: ref_49 article-title: Effects of Clostridium butyricum Capsules Combined with Rosuvastatin on Intestinal Flora, Lipid Metabolism, Liver Function and Inflammation in NAFLD Patients publication-title: Cell Mol. Biol. doi: 10.14715/cmb/2021.67.5.9 – ident: ref_61 doi: 10.3390/nu12113225 – volume: 27 start-page: 41 year: 2018 ident: ref_36 article-title: A Multi-strain Probiotic Reduces the Fatty Liver Index, Cytokines and Aminotransferase levels in NAFLD Patients: Evidence from a Randomized Clinical Trial publication-title: J. Gastrointestin. Liver Dis. doi: 10.15403/jgld.2014.1121.271.kby – volume: 12 start-page: 256 year: 2013 ident: ref_39 article-title: Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study publication-title: Ann. Hepatol. doi: 10.1016/S1665-2681(19)31364-X – volume: 97 start-page: 7386 year: 2014 ident: ref_25 article-title: Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease publication-title: J. Dairy Sci. doi: 10.3168/jds.2014-8500 – ident: ref_60 doi: 10.3390/ijms23042325 – volume: 620 start-page: 381 year: 2023 ident: ref_16 article-title: Synergy and oxygen adaptation for development of next-generation probiotics publication-title: Nature doi: 10.1038/s41586-023-06378-w – volume: 109 start-page: 1611 year: 2019 ident: ref_40 article-title: Yogurt improves insulin resistance and liver fat in obese women with nonalcoholic fatty liver disease and metabolic syndrome: A randomized controlled trial publication-title: Am. J. Clin. Nutr. doi: 10.1093/ajcn/nqy358 – volume: 86 start-page: e03004 year: 2020 ident: ref_59 article-title: Akkermansia muciniphila Prevents Fatty Liver Disease, Decreases Serum Triglycerides, and Maintains Gut Homeostasis publication-title: Appl. Environ. Microbiol. doi: 10.1128/AEM.03004-19 – volume: 24 start-page: 331 year: 2018 ident: ref_48 article-title: Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease publication-title: Clin. Mol. Hepatol. doi: 10.3350/cmh.2018.0006 – volume: 13 start-page: 1047570 year: 2022 ident: ref_57 article-title: Akkermansia muciniphila suppressing nonalcoholic steatohepatitis associated tumorigenesis through CXCR6(+) natural killer T cells publication-title: Front. Immunol. doi: 10.3389/fimmu.2022.1047570 – ident: ref_10 doi: 10.3390/nu13093211 – volume: 12 start-page: 678360 year: 2021 ident: ref_66 article-title: Prebiotic Inulin and Sodium Butyrate Attenuate Obesity-Induced Intestinal Barrier Dysfunction by Induction of Antimicrobial Peptides publication-title: Front. Immunol. doi: 10.3389/fimmu.2021.678360 – volume: 176 start-page: 113869 year: 2021 ident: ref_23 article-title: Pathophysiological communication between hepatocytes and non-parenchymal cells in liver injury from NAFLD to liver fibrosis publication-title: Adv. Drug Deliv. Rev. doi: 10.1016/j.addr.2021.113869 – volume: 191 start-page: 187 year: 2022 ident: ref_7 article-title: Gut microbiome and non-alcoholic fatty liver disease publication-title: Prog. Mol. Biol. Transl. Sci. doi: 10.1016/bs.pmbts.2022.07.004 – volume: 18 start-page: 698 year: 2017 ident: ref_35 article-title: Treatment efficacy of a probiotic preparation for non-alcoholic steatohepatitis: A pilot trial publication-title: J. Dig. Dis. doi: 10.1111/1751-2980.12561 – volume: 12 start-page: 2453 year: 2022 ident: ref_54 article-title: The anti-inflammatory effects of Akkermansia muciniphila and its derivates in HFD/CCL4-induced murine model of liver injury publication-title: Sci. Rep. doi: 10.1038/s41598-022-06414-1 – volume: 28 start-page: 100769 year: 2023 ident: ref_46 article-title: Oral 24-week probiotics supplementation did not decrease cardiovascular risk markers in patients with biopsy proven NASH: A double-blind placebo-controlled randomized study publication-title: Ann. Hepatol. doi: 10.1016/j.aohep.2022.100769 – ident: ref_63 doi: 10.3390/diseases7010027 – ident: ref_70 doi: 10.1371/journal.pone.0263931 – volume: 39 start-page: 53 year: 2020 ident: ref_31 article-title: The effects of Bacillus coagulans supplementation in patients with non-alcoholic fatty liver disease: A randomized, placebo-controlled, clinical trial publication-title: Clin. Nutr. ESPEN doi: 10.1016/j.clnesp.2020.06.020 – ident: ref_38 doi: 10.3390/nu13093192 – ident: ref_8 doi: 10.3390/ph16050712 – ident: ref_64 doi: 10.1016/j.biopha.2021.111235 – volume: 35 start-page: 500 year: 2016 ident: ref_27 article-title: Effects of Multistrain Probiotic Supplementation on Glycemic and Inflammatory Indices in Patients with Nonalcoholic Fatty Liver Disease: A Double-Blind Randomized Clinical Trial publication-title: J. Am. Coll. Nutr. doi: 10.1080/07315724.2015.1031355 – ident: ref_56 doi: 10.3389/fmicb.2023.1123547 – ident: ref_17 doi: 10.3390/microorganisms10020297 – ident: ref_6 doi: 10.3389/fcimb.2022.997018 – volume: 7 start-page: 679 year: 2021 ident: ref_15 article-title: An Update on the Efficacy and Functionality of Probiotics for the Treatment of Non-Alcoholic Fatty Liver Disease publication-title: Engineering doi: 10.1016/j.eng.2020.01.017 – volume: 99 start-page: e21464 year: 2020 ident: ref_41 article-title: Protective effect of probiotics in patients with non-alcoholic fatty liver disease publication-title: Medicine doi: 10.1097/MD.0000000000021464 – ident: ref_21 doi: 10.3390/nu12092762 – ident: ref_52 doi: 10.1128/Spectrum.00484-21 – ident: ref_19 doi: 10.3390/biomedicines9060687 – volume: 19 start-page: 994 year: 2019 ident: ref_20 article-title: Mechanisms of beneficial effects of exercise training on non-alcoholic fatty liver disease (NAFLD): Roles of oxidative stress and inflammation publication-title: Eur. J. Sport Sci. doi: 10.1080/17461391.2019.1571114 – volume: 13 start-page: 1087260 year: 2022 ident: ref_62 article-title: Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD) publication-title: Front. Endocrinol. doi: 10.3389/fendo.2022.1087260 – ident: ref_53 doi: 10.3390/antiox10122001 – volume: 158 start-page: 1597 year: 2020 ident: ref_33 article-title: Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease publication-title: Gastroenterology doi: 10.1053/j.gastro.2020.01.031 – volume: 11 start-page: 533 year: 2018 ident: ref_4 article-title: Obesity and nonalcoholic fatty liver disease: Current perspectives publication-title: Diabetes Metab. Syndr. Obes. doi: 10.2147/DMSO.S146339 – volume: 79 start-page: 76 year: 2022 ident: ref_13 article-title: Outlook on next-generation probiotics from the human gut publication-title: Cell. Mol. Life Sci. doi: 10.1007/s00018-021-04080-6 – ident: ref_18 doi: 10.3390/microorganisms10020452 – volume: 99 start-page: 535 year: 2014 ident: ref_26 article-title: Synbiotic supplementation in nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled pilot study publication-title: Am. J. Clin. Nutr. doi: 10.3945/ajcn.113.068890 – ident: ref_11 doi: 10.3389/fcimb.2022.863949 – ident: ref_55 doi: 10.3390/nu14142945 – volume: 158 start-page: 1984 year: 2020 ident: ref_71 article-title: Therapeutic Landscape for NAFLD in 2020 publication-title: Gastroenterology doi: 10.1053/j.gastro.2020.01.051 – volume: 9 start-page: 5688 year: 2019 ident: ref_37 article-title: Randomized, Double-blind, Placebo-controlled Study of a Multispecies Probiotic Mixture in Nonalcoholic Fatty Liver Disease publication-title: Sci. Rep. doi: 10.1038/s41598-019-42059-3 – volume: 15 start-page: 2221485 year: 2023 ident: ref_58 article-title: Akkermansia muciniphila inhibits nonalcoholic steatohepatitis by orchestrating TLR2-activated γδT17 cell and macrophage polarization publication-title: Gut Microbes doi: 10.1080/19490976.2023.2221485 – ident: ref_5 doi: 10.3390/biomedicines11020640 – volume: 245 start-page: 425 year: 2020 ident: ref_68 article-title: SCFAs alleviated steatosis and inflammation in mice with NASH induced by MCD publication-title: J. Endocrinol. doi: 10.1530/JOE-20-0018 – volume: 58 start-page: 1735 year: 2019 ident: ref_32 article-title: Histological improvement of non-alcoholic steatohepatitis with a prebiotic: A pilot clinical trial publication-title: Eur. J. Nutr. doi: 10.1007/s00394-018-1721-2 – ident: ref_65 doi: 10.1016/j.biopha.2023.114300 – ident: ref_34 doi: 10.1186/s12876-021-01660-5 – volume: 126 start-page: 108590 year: 2019 ident: ref_14 article-title: A potential species of next-generation probiotics? The dark and light sides of Bacteroides fragilis in health publication-title: Food. Res. Int. doi: 10.1016/j.foodres.2019.108590 – volume: 10 start-page: 89 year: 2019 ident: ref_3 article-title: Pediatric non-alcoholic fatty liver disease: Current perspectives on diagnosis and management publication-title: Pediatr. Health Med. Ther. doi: 10.2147/PHMT.S188989 – volume: 4 start-page: 531 year: 2013 ident: ref_24 article-title: Effect of a Probiotic and Metformin on Liver Aminotransferases in Non-alcoholic Steatohepatitis: A Double Blind Randomized Clinical Trial publication-title: Int. J. Prev. Med. – volume: 6 start-page: e000315 year: 2019 ident: ref_44 article-title: High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (NAFLD): A randomised, double-blind, proof of concept study publication-title: BMJ Open. Gastroenterol. doi: 10.1136/bmjgast-2019-000315 – volume: 152 start-page: 408 year: 2022 ident: ref_47 article-title: A Specifically Tailored Multistrain Probiotic and Micronutrient Mixture Affects Nonalcoholic Fatty Liver Disease-Related Markers in Patients with Obesity after Mini Gastric Bypass Surgery publication-title: J. Nutr. doi: 10.1093/jn/nxab392 – volume: 117 start-page: 662 year: 2017 ident: ref_29 article-title: Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: A pilot, randomised, double-blind, placebo-controlled, clinical trial publication-title: Br. J. Nutr. doi: 10.1017/S0007114517000204 – ident: ref_12 doi: 10.1155/2022/5633403 |
SSID | ssj0000913809 |
Score | 2.3346436 |
SecondaryResourceType | review_article |
Snippet | Non-alcoholic fatty liver disease (NAFLD) and its progressive stage, non-alcoholic steatohepatitis (NASH), are becoming one of the most common chronic liver... |
SourceID | doaj pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 329 |
SubjectTerms | antioxidant Clinical outcomes Comparative analysis Digestive system Fatty acids Fatty liver Gastrointestinal tract Hepatitis Immune response Inflammation Intervention Intestinal microflora intestinal microorganisms intestines lifestyle Lifestyles Lipids liver Liver diseases Medical Subject Headings-MeSH Meta-analysis Metabolism Microbiomes Microbiota NAFLD/NASH next-generation probiotics (NGPs) Oxidative stress pathogenesis Patients Physical activity Prebiotics Probiotics Review short-chain fatty acids (SCFAs) Systematic review therapeutics traditional probiotics weight loss |
SummonAdditionalLinks | – databaseName: DOAJ Open Access Full Text dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1di9QwFA2yT_ogrp_jrhJB0H0o2zRNk_g2ug6D7A7iurBvJUkTdkBacbqg_8yf571Jp07FjxdfCm0vJc29yT2nuT0h5LljVSgaKTJnuM9K0bjMClPAoQoQI8ih8W_ks1W1vCjfXYrLna2-sCYsyQOnjjuWAbKUU0ZKFsqKB2MBAfNSQ-gYplT8dQ_S2A6ZinOwZlzlOqk0cuD1xwaLB7_ijJ3ziCd_ZqEo1v87hPlroeRO5lncIbcHyEjnqan75IZv75JbO0KC98j3D6jLRLtAIfc06_R9j5q2oStktklbGq_S91F3CbWZKZytujabp01y144uTN9_o6dYqUFP0sINfbmaL05PjtKzJtZYCdx3Vx5Lsvv1Bi3Pl0ev6Jyej-rQNC09DC2JBef0zPcm22qh3CcXi7cf3yyzYU-GzAmm-qwISkiZe9uUwQJ59AC3Ci3yYF3JgrKVlNDd3hrOhOfocAsQw1njowRywx-QvbZr_SNCnXCaBy55pULJGmWKMojCS64r6fMqzEi29VHtBsFy3DfjUw3EBX1aT306Iy9G-89JquOPlq_R5aMVSmzHCxB49RB49b8Cb0YOtwFTD-N-UxcaCKjWwCln5Nl4G0YsLsOY1nfXmzqSWpw4i7_ZoOpRWUh4zsMUg2NrOSAsDUR0RtQkOievM73Trq-icjgDwqqYVI__RwcckJsFILxYkCcPyV7_5do_AYTW26dxMP4AJJA5-w priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fa9UwFA7z7kUfxN9enRJB0D2U3SZNkwoid26Xi2xlbA72VtI0cReknbsd6H_mn-c5SdutonsptDmEtOfk5HzJ6XcIeWvi1LFKishobqNEVCYqhWZwSR3YCGJo_Bv5ME-Xp8mXM3G2QfL-XxhMq-x9onfUVWNwj3yHATjGVEmRfbr4EWHVKDxd7Uto6K60QvXRU4zdIZsMqypPyObufn50POy6IAummmWBvZED3t_RmFT4Ez35jPs483p18iT-_4o8_06gvLEiLR6Q-10oSedB9w_Jhq0fkXs3CAYfk9_HyNdEG0dhTapWYd-P6rqiOSLewDmNT-mR52NCzmYKd3lTR_NQPHdl6EK37S96gBkcdC8c6ND3-XxxsLcd-hpJY4Zw25xbTNVuV2uUPFluf6BzejKwRtNwJNGNxCei00Pb6qjnSHlCThf7Xz8vo65WQ2Tge7cRc0pIObNllbgSQKWFMIxlYuZKk8ROlamU8LltqXksLEdDKCH0MKW2nhq54k_JpG5q-5xQI0zGHZc8VS6JK6VZ4gSzkmeptLPUTUnU66gwHZE51tP4XgCgQZ0WY51OybtB_iJQePxXchdVPkgh9bZ_0Fx-K7qZXEgHYZNRWsrYJSl3ugRIxpMMfJmOlYJOtnqDKTp_sC6urXdK3gzNMJPxeEbXtrlaFx7sokNlt8kgG1LCJPTzLNjgMFoOkVcGAHVK1Mg6R68zbqlX555RPAYgq2KpXtw-9pfkLoOYzqfgyS0yaS-v7CuIydrydTfR_gA1nDlx priority: 102 providerName: ProQuest |
Title | Roles of Traditional and Next-Generation Probiotics on Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A Systematic Review and Network Meta-Analysis |
URI | https://www.ncbi.nlm.nih.gov/pubmed/38539862 https://www.proquest.com/docview/2987199259 https://www.proquest.com/docview/3014004882 https://www.proquest.com/docview/3040434279 https://pubmed.ncbi.nlm.nih.gov/PMC10968178 https://doaj.org/article/7f008c8a771f463fab974349319a1889 |
Volume | 13 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 2076-3921 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000913809 issn: 2076-3921 databaseCode: KQ8 dateStart: 20120101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2076-3921 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000913809 issn: 2076-3921 databaseCode: DOA dateStart: 20120101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2076-3921 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000913809 issn: 2076-3921 databaseCode: M~E dateStart: 20120101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 2076-3921 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000913809 issn: 2076-3921 databaseCode: RPM dateStart: 20120101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 2076-3921 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000913809 issn: 2076-3921 databaseCode: BENPR dateStart: 20120301 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 2076-3921 dateEnd: 20250731 omitProxy: true ssIdentifier: ssj0000913809 issn: 2076-3921 databaseCode: M48 dateStart: 20120901 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3va9QwGA66fdEP4m9vziOCoPtQvSRtkwoiN7fjkF0Zmwf7VtI0cQejdXcdbP-Zf57vm_bqKqf4pdD2JbTJm-R5mqdPCHljWOx4IaPAaGGDMCpMkEeawyF2kCPIofFv5FkaT-fh17Po7Lf-qa3A1UZqh_tJzZcX768vbz5Dh_-EjBMo-weNusBrHIxHgid3yTbMShwzfNZCfT8qJ0wor_jgQN0DgAWs8XDcUERvjvJW_pvw558yylvz0uQhedACSjpuMuARuWPLx-T-LZvBJ-TnCbo20cpRmJmKRfP1j-qyoCny3sZ5Gq_SY-_KhM7NFM7SqgzGzRa6C0Mnuq5v6BHqOOhBs6xD36XjydHBXlNWLxp1wnV1blGwXS9WGHk63ftIx_S0846mzcJE-yRejk5nttbB2inlKZlPDr99mQbtjg2BiZiqA-5UJOXI5kXocqCWFsAYT6KRy03InMpjKaG6ba4Fi6zAdMgBgJhcW2-QXIhnZKusSvuCUBOZRDghRaxcyAqleegibqVIYmlHsRuQYN1GmWntzHFXjYsMaA22adZv0wF528X_aIw8_hq5j03eRaEBt79QLb9nbX_OpAPwZJSWkrkwFk7nQMxEmMCIpplSUMjuOmGydVJnPAF6miTAOAfkdXcb-jMu0ujSVlerzFNeHFb5v2LQEynkEsp53uRg97QC8FcCNHVAVC87e6_Tv1Muzr2vOAM6q5hUO_9dVS_JPQ4gz2vy5C7ZqpdX9hWAtDofku39w_T4ZOg_cgx9X_wFHh0-Og |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKewAOiDcLBYwEgh6iJnYSJ0gV2rJdbeluVPUh9ZY6jk1XQknppoL-M078NmacRxsEvfUSKclk5GjG87DH3xDyVnmhYbkIHCW5dvwgV04WSAaX0ICOYA6Np5FnSTg59L8cBUdL5Hd7FgbLKlubaA11XipcI19nkBxjqWQQfzr97mDXKNxdbVtoyKa1Qr5hIcaagx07-uIHpHCLje0RyPsdY-Otg88Tp-ky4CigrBxmokAIV2e5bzJIhzQEECwOXJMp3zNRFgrBeawzyb1Ac_yFDJymyqS2oL45B763yAp8xWFWrWxuJbt73SoPom5GblyjRQIbd11iEeNP9Bwut3HtpTe0TQP-Fen-XbB5xQOO75N7TehKh7WuPSBLunhI7l4BNHxEfu0hPhQtDQUfmM_rdUYqi5wmmGHXGNf4lO5a_CfEiKZwl5SFM6yb9c4VHcuquqBTrBiho3oDiX5IhuPpaK3m1aPGiuSqPNFYGl7NF0i5P1n7SId0v0OppvUWSDMSW_hOZ7qSTovJ8pgc3ojUnpDloiz0M0JVoGJuuOBhZHwvjyTzTcC04HEotBuaAXFaGaWqAU7H_h3fUkigUKZpX6YD8r6jP60hQ_5LuYki76gQ6ts-KM--po3lSIWBME1FUgjP-CE3MoMUkPsx2E7pRREwWW0VJm3szyK9nC0D8qZ7DZYDt4NkocvzRWqTazTg7DoaRF_ymQA-T2sd7EbLIdKLISEekKinnb3f6b8p5icWwdyDxDnyRPT8-rG_JrcnB7NpOt1Odl6QOwziSVv-J1bJcnV2rl9CPFhlr5pJR8nxTc_zP4JXda4 |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9MwELdGJyF4QPynMMBIINhD1MROYgdpQh1d1bEuqjYm7S04jr1VmpKxZoJ9Mz4Dn4q7_NuKYG97qdTkZDm689397PPvCHmrvdCyTASOVtw4fpBpJw0Ug5_Qgo0ghsbbyLtxODnwvxwGhyvkd3sXBssqW59YOeqs0LhHPmAAjrFUMogGtimLmI3Gn06_O9hBCk9a23YaqmmzkG1UdGPNJY8dc_ED4NxiY3sEun_H2Hjr6-eJ03QccDRIlg6zMhDCNWnm2xSgkYFkgkWBa1Pte1amoRCcRyZV3AsMx89JIYDqVJmK4DfjMO4tsirwvmiPrG5uxbO9bscHGTilG9XMkTCMO1BY0PgTo4jLqxz3MjJWDQT-lfX-Xbx5JRqO75N7TRpLh7XdPSArJn9I7l4hN3xEfu0hVxQtLIV4mM3rPUeq8ozGiLZrvmt8SmcVFxTyRVP4Fxe5M6wb9841HauyvKBTrB6ho_owiX6Ih-PpaL0ea0kaq5PL4thgmXg5X6Dk_mT9Ix3S_Y6xmtbHIc1MqiJ4umtK5bT8LI_JwY1o7Qnp5UVunhGqAx1xywUPpfW9TCrm24AZUGgojBvaPnFaHSW6IVHHXh4nCYAp1GmyrNM-ed_Jn9b0If-V3ESVd1JI-109KM6OksaLJMJCyqalEsKzfsitSgEOcj8CP6o8KWGQtdZgksYXLZLLldMnb7rX4EXwaEjlpjhfJBXQRmfOrpNBJiafCRjnaW2D3Ww5ZH0RgOM-kUvWufQ5y2_y-XHFZu4BiJaekM-vn_trchvWezLdjndekDsMUsuqElCskV55dm5eQmpYpq-aNUfJt5te5n8A8a556A |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Roles+of+Traditional+and+Next-Generation+Probiotics+on+Non-Alcoholic+Fatty+Liver+Disease+%28NAFLD%29+and+Non-Alcoholic+Steatohepatitis+%28NASH%29%3A+A+Systematic+Review+and+Network+Meta-Analysis&rft.jtitle=Antioxidants&rft.au=Zhu%2C+Yuezhi&rft.au=Tan%2C+Jen+Kit&rft.au=Liu%2C+Jia&rft.au=Goon%2C+Jo+Aan&rft.date=2024-03-07&rft.issn=2076-3921&rft.eissn=2076-3921&rft.volume=13&rft.issue=3&rft.spage=329&rft_id=info:doi/10.3390%2Fantiox13030329&rft.externalDBID=n%2Fa&rft.externalDocID=10_3390_antiox13030329 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2076-3921&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2076-3921&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2076-3921&client=summon |